TG Therapeutics, Inc. (TGTX) Cash Flow Statement

The consistent failure of net income to convert into positive operating cash flow indicates that the company's profitability is heavily reliant on non-cash items or accounting adjustments. Investors should monitor whether this divergence narrows as the Briumvi launch matures, as current trends suggest the core business remains cash-consumptive despite headline earnings.

The volatility in FCF, punctuated by occasional positive quarters, appears to be driven more by timing differences in working capital than by consistent operational efficiency. This pattern suggests that the company's cash flow profile is not yet stabilized, leaving it exposed to liquidity risks if revenue growth fails to outpace rising commercial costs.

The recurring negative working capital changes suggest that the company is likely building inventory or extending payment terms to support its market penetration strategy. This aggressive use of cash to fuel growth warrants further investigation into whether these investments will yield the expected long-term persistence in patient adoption.

This capital deployment strategy may indicate management's confidence in the Briumvi franchise, yet it simultaneously depletes the cash reserves necessary to navigate potential regulatory or competitive headwinds. Investors should consider whether such aggressive buybacks are premature given the company's ongoing reliance on external financing to fund its operations.